Tessa Therapeutics is a biotechnology company developing t-cell immunotherapies therapies for the treatment of cancer that is headquartered in Singapore and was founded in 2011 by Malcolm Brenner and Andrew Khoo.
Product candidates in development by Tessa Therapeutics include: Epstein-Barr Virus-Specific T Cells (EBVSTs) for Nasopharyngeal Cancer (NPC), Human Papillomavirus-Specific T Cells (HPVSTs) for HPV-Associated Cancers, HER2-CARTs + Oncolytic & Helper-Dependent Adenovirus for HER2-positive solid tumors, Multi CAR VSTs for Pediatric Gliomas, and Allogeneic CD30-Chimeric Antigen Receptor (CAR) Epstein-Bar Virus-Specific T cells (EBVSTs) for CD30-Positive Lymphomas.
On December 19, 2017 Tessa Therapeutics announced raising a $80 million financing round from Temasek (lead investor), EDBI, Karst Peak Capital, Heliconia, Heritas, and other investors. The company plans on using their funding to continue advancing their clinical pipeline and start new clinical trials based on the company's Virus Specific T cell (VST) platform. The CEO and co-founder of Tessa therapeutics, Andrew Khoo, made the following statement regarding the new financing:
We are very pleased with the success in this financing round which validates our work and continued progress in the development of Tessa's Virus Specific T cell platform technology and clinical pipeline. Tessa plans to expand its global presence and advance next generation cellular therapies targeting a wide range of cancer indications.
Co-Founder & Chairman of Scientific Advisory Board
Founder & CEO
Documentaries, videos and podcasts
- ImmunotherapyImmunotherapy aims to treat disease through activation or suppression of an immune response. For example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.
- CancerDisease of cellular proliferation characterized by uncontrolled cellular proliferation, local tissue invasion, and disseminated metastasis